Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study

Christopher B. Nahm, John Turchini, Nigel Jamieson, Elizabeth Moon, Loretta Sioson, Malinda Itchins, Jennifer Arena, Emily Colvin, Viive M. Howell, Nick Pavlakis, Stephen Clarke, Jaswinder S. Samra, Anthony J. Gill, Anubhav Mittal*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    19 Citations (Scopus)


    Background: Up to 60% of patients who undergo curative-intent pancreatic ductal adenocarcinoma (PDAC) resection experience disease recurrence within six months. We recently published a systematic review of prognostic immunohistochemical biomarkers in PDAC and shortlisted a panel of those reported with the highest level of evidence, including p53, p16, Ca-125, S100A4, FOXC1, EGFR, mesothelin, CD24 and UPAR. This study aims to discover and validate the prognostic significance of a combinatorial panel of tumor biomarkers in patients with resected PDAC. Methods: Patients who underwent PDAC resection were included from a single institution discovery cohort and a multi-institutional validation cohort. Tumors in the discovery cohort were stained immunohistochemically for all nine shortlisted biomarkers. Biomarkers significantly associated with overall survival (OS) were reevaluated as a combinatorial panel in both discovery and validation cohorts for its prognostic significance. Results: 224 and 191 patients were included in the discovery and validation cohorts, respectively. In both cohorts, S100A4, Ca-125 and mesothelin expression were associated with shorter OS. In both cohorts, the number of these biomarkers expressed was significantly associated with OS (discovery cohort 36.8 vs. 26.4 vs 16.3 vs 12.8 months, P < 0.001; validation cohort 25.2 vs 18.3 vs 13.6 vs 11.9 months, P = 0.008 for expression of zero, one, two and three biomarkers, respectively). On multivariable analysis, expression of at least one of three biomarkers was independently associated with shorter OS. Conclusion: Combinations of S100A4, Ca-125 and mesothelin expression stratify survival after resection of localized PDAC. Co-expression of all three biomarkers is associated with the poorest prognostic outcome.

    Original languageEnglish
    Pages (from-to)218-224
    Number of pages7
    JournalEuropean Journal of Surgical Oncology
    Issue number2
    Publication statusPublished - 1 Feb 2019


    • Biomarker
    • Pancreatectomy
    • Pancreatic cancer
    • Survival


    Dive into the research topics of 'Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study'. Together they form a unique fingerprint.

    Cite this